Iteos Therapeutics Inc Net Income per Employee (ITOS), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Iteos Therapeutics Inc   (NASDAQ: ITOS)
 

Iteos Therapeutics Inc Net Income per Employee

ITOS's Quarterly Results, Trends, Rankings, Statistics
Iteos Therapeutics Inc recorded a cumulative net loss of $-202 million during 12 month ending in the second quarter 2025.
The Healthcare sector has seen employees of 94 other companies achieving higher income per employee. While Iteos Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 1722 to 3740.


What is Income per Employee Ratio?






ITOS Net Income per Employee (Jun 30 2025)
II. Quarter
(Mar 31 2025)
I. Quarter
(Dec 31 2024)
IV. Quarter
(Sep 30 2024)
III. Quarter
(Jun 30 2024)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -1,289,248 -833,191 -856,140 -772,306 -688,758
ITOS's Total Ranking # 3740 # 1722 # 2767 # 2374 # 2891
Seq. Net Income Change - - - - -


ITOS Net Income per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 95
Healthcare Sector # 655
Overall Market # 3740

Net Income per Employee Statistics
High Average Low
$ 2,100,140 $ 58,341 $ -1,289,248
(Jun 30 2022)   (Jun 30 2025)







Companies with similar Income per Employee for 12 month ending Jun 30 2025, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2025Number of Employees Jun 30 2025


Date modified: 2026-09-08T15:22:15+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.